Table 1.
Baseline characteristics.
| TMA (n = 15) | Non-TMA (n = 54) | p-Value | |||
|---|---|---|---|---|---|
| Baseline characteristics | Median (IQR) | Median (IQR) | |||
| Female (n, %) | 9 | (60) | 18 | (33.3) | 0.063 |
| Age (years) | 66 | (45–72) | 70 | (62–76) | 0.112 |
| Body-mass index (kg/m2) | 23.2 | (20.8–30.4) | 25.8 | (22.4–28.9) | 0.531 |
| Height (m) | 1.68 | (1.63–1.75) | 1.75 | (1.65–1.85) | 0.098 |
| Weight (kg) | 76 | (63–85) | 78 | (69–94) | 0.284 |
| Diagnosis on admission | n (%) | n (%) | p-value | ||
| Aortic valve disease | |||||
| Aortic stenosis | 1 | (6.7) | 10 | (18.5) | 0.434 |
| Aortic insufficiency | 8 | (53.3) | 19 | (35.2) | 0.240 |
| Aortic endocarditis | 2 | (13.3) | 6 | (11.1) | 1.000 |
| Mitral valve disease | |||||
| Mitral stenosis | 0 | (0.0) | 5 | (9.3) | 0.578 |
| Mitral insufficiency | 5 | (33.3) | 23 | (42.6) | 0.568 |
| Mitral endocarditis | 0 | (0.0) | 5 | (9.3) | 0.578 |
| Tricuspid valve disease | |||||
| Tricuspid insufficiency | 3 | (20.0) | 14 | (25.9) | 0.746 |
| Tricuspid stenosis | 0 | (0.0) | 0 | (0.0) | NA |
| Aortic disease | |||||
| Aortic aneurysm | 7 | (46.7) | 8 | (14.8) | 0.014 |
| Aortic dissection Type A | 1 | (6.7) | 9 | (16.7) | 0.442 |
| Coronary artery disease (CAD) | 7 | (46.7) | 34 | (57.4) | 0.561 |
| Reduced LVEF | 4 | (26.7) | 27 | (42.6) | 0.373 |
| End stage heart failure | 0 | (0.0) | 11 | (16.7) | 0.189 |
| Previous heart surgery | 7 | (46.7) | 19 | (33.3) | 0.375 |
| TMA (n = 15) | Non-TMA (n = 54) | p-Value | |||
| Cardiovascular history & risk factors | n (%) | n (%) | |||
| Diabetes mellitus (Type 1 or 2) | 2 | (13.3) | 12 | (22.2) | 0.718 |
| Arterial hypertension | 10 | (66.7) | 38 | (70.4) | 0.761 |
| Hypercholesterinemia | 10 | (66.7) | 27 | (50.0) | 0.381 |
| Family history for CAD | 6 | (40.0) | 6 | (14.8) | 0.063 |
| Obesity | 4 | (26.7) | 17 | (31.5) | 1.000 |
| History of smoking | 6 | (40.0) | 23 | (42.6) | 1.000 |
| Macroangiopathy (cerebral or peripheral) | 10 | (66.7) | 28 | (51.9) | 0.386 |
| Renal history | n (%) | n (%) | p-value | ||
| Chronic kidney disease (eGFR≤ 60ml/min) | 3 | (20.0) | 26 | (48.2) | 0.076 |
| Other pathologies | n (%) | n (%) | p-value | ||
| Autoimmune disease | 3 | (20.0) | 3 | (5.7) | 0.112 |
| History of malignancy | 1 | (6.7) | 9 | (16.7) | 0.442 |
| Medication | n (%) | n (%) | p-value | ||
| ACE-Inhibitors/AT1-Blockers | 8 | (53.3) | 31 | (57.4) | 0.778 |
| Beta blockers | 9 | (60.0) | 38 | (70.3) | 0.535 |
| Statins | 8 | (53.3) | 24 | (44.4) | 0.572 |
| Aspirin/Clopidogrel | 7 | (46.7) | 24 | (44.4) | 1.000 |
| Ticlopidine | 0 | (0.0) | 1 | (1.9) | 1.000 |
| OAC (Marcumar/NOACs) | 6 | (40.0) | 25 | (46.3) | 0.773 |
| Immunosuppression | 2 | (13.3) | 2 | (3.7) | 0.204 |
TMA: Thrombotic microangiopathy, kg: kilograms, m: meters, kg/m2: kilograms per square meters, eGFR: estimated glomerular filtration rate, CAD: coronary artery disease, LVEF: left ventricular ejection fraction, ACE-Inhibitors: angiotensin-converting enzyme inhibitors; AT1-Blockers: angiotensin II type 1 receptor blockers, NOACs: novel oral anticoagulants, OAC: oral anticoagulants, NA: not applicable.